Literature DB >> 24574397

Activities of transmitted/founder and chronic clade B HIV-1 Vpu and a C-terminal polymorphism specifically affecting virion release.

Moein Jafari1, John Guatelli, Mary K Lewinski.   

Abstract

UNLABELLED: Acute HIV-1 infection is characterized by a type I interferon response, resulting in the induction of host restriction factors. HIV-1 has evolved to counteract these factors, and one such adaptation, the ability of Vpu to counteract BST2/tetherin, is associated with the evolution of simian immunodeficiency virus (SIVcpz) into pandemic group M human immunodeficiency virus type 1 (HIV-1). During transmission between individuals, very few viruses or even a single virus, the "transmitted/founder" (T/F) virus, gives rise to the new infection, but in the new host the selective pressure of the immune response yields the diverse "quasispecies" of chronic infection. Here we examine the functional characteristics of Vpu proteins encoded by T/F viruses compared to acute and chronic viruses from longitudinally sampled subjects. The studied T/F Vpu proteins showed a trend toward optimized CD4 downregulation compared to chronic Vpu proteins but did not differ substantially in their ability to downregulate BST2 or enhance virion release, although individual clones from each group were impaired in these activities. Analysis of the functionally impaired clones identified a C-terminal residue, W76, as important specifically for Vpu enhancement of virion release. Primary Vpu clones encoding a W76G polymorphism, or site-directed mutants encoding a W76G substitution, were impaired in their ability to enhance virion release, but they were not defective for BST2 surface downregulation. Conversely, the virion release function of impaired primary clones was restored by creating a G76W substitution. The identification of W76 as important for virion release enhancement that is independent of BST2 surface downregulation supports the potential to mechanistically separate these functions of Vpu. IMPORTANCE: To establish infection in a host, HIV-1 must evade the host's immune response, including the production of antiviral factors. HIV-1 encodes proteins that antagonize these defenses, including Vpu. Vpu counteracts the host protein BST2, which blocks the release of progeny viruses from the host cell. To determine the importance of Vpu activity to HIV-1 transmission, this study assessed the functionality of Vpu from viruses isolated soon after transmission ("transmitted/founder" viruses) compared to isolates from chronic infection. Although the anti-BST2 activity of Vpu proteins from the tested transmitted/founder viruses did not differ from the activity of the chronic Vpu proteins, the transmitted/founder Vpu proteins trended toward having superior activity against another host protein, CD4. Further, this study identified an amino acid near the C terminus of Vpu that is specifically important for Vpu's ability to enhance the release of progeny virus from the host cell, supporting the notion of a new mechanism for this function of Vpu.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24574397      PMCID: PMC3993827          DOI: 10.1128/JVI.03472-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Cell surface CD4 inhibits HIV-1 particle release by interfering with Vpu activity.

Authors:  S Bour; C Perrin; K Strebel
Journal:  J Biol Chem       Date:  1999-11-19       Impact factor: 5.157

2.  The membrane-proximal tyrosine-based sorting signal of human immunodeficiency virus type 1 gp41 is required for optimal viral infectivity.

Authors:  John R Day; Carsten Münk; John C Guatelli
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

3.  Immunological changes in primary HIV-1 infection.

Authors:  H Gaines; M A von Sydow; L V von Stedingk; G Biberfeld; B Böttiger; L O Hansson; P Lundbergh; A B Sönnerborg; J Wasserman; O O Strannegåard
Journal:  AIDS       Date:  1990-10       Impact factor: 4.177

4.  The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release.

Authors:  T Klimkait; K Strebel; M D Hoggan; M A Martin; J M Orenstein
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

5.  HIV-1 reverse transcription. A termination step at the center of the genome.

Authors:  P Charneau; G Mirambeau; P Roux; S Paulous; H Buc; F Clavel
Journal:  J Mol Biol       Date:  1994-09-02       Impact factor: 5.469

6.  Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line.

Authors:  J P Morgenstern; H Land
Journal:  Nucleic Acids Res       Date:  1990-06-25       Impact factor: 16.971

7.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

8.  Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity.

Authors:  Maxime Veillette; Anik Désormeaux; Halima Medjahed; Nour-Elhouda Gharsallah; Mathieu Coutu; Joshua Baalwa; Yongjun Guan; George Lewis; Guido Ferrari; Beatrice H Hahn; Barton F Haynes; James E Robinson; Daniel E Kaufmann; Mattia Bonsignori; Joseph Sodroski; Andrés Finzi
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

9.  The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains.

Authors:  U Schubert; S Bour; A V Ferrer-Montiel; M Montal; F Maldarell; K Strebel
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

10.  Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter.

Authors:  J S Harms; G A Splitter
Journal:  Hum Gene Ther       Date:  1995-10       Impact factor: 5.695

View more
  23 in total

1.  Membrane Anchoring by a C-terminal Tryptophan Enables HIV-1 Vpu to Displace Bone Marrow Stromal Antigen 2 (BST2) from Sites of Viral Assembly.

Authors:  Mary K Lewinski; Moein Jafari; Hua Zhang; Stanley J Opella; John Guatelli
Journal:  J Biol Chem       Date:  2015-03-10       Impact factor: 5.157

2.  HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.

Authors:  François M Pujol; Vibor Laketa; Florian Schmidt; Markus Mukenhirn; Barbara Müller; Steeve Boulant; Dirk Grimm; Oliver T Keppler; Oliver T Fackler
Journal:  J Virol       Date:  2016-07-11       Impact factor: 5.103

3.  In vitro functional assessment of natural HIV-1 group M Vpu sequences using a universal priming approach.

Authors:  Asa Rahimi; Gursev Anmole; Maribel Soto-Nava; Tania Escamilla-Gomez; Tristan Markle; Steven W Jin; Guinevere Q Lee; P Richard Harrigan; David R Bangsberg; Jeffrey Martin; Santiago Avila-Rios; Gustavo Reyes-Teran; Mark A Brockman; Zabrina L Brumme
Journal:  J Virol Methods       Date:  2016-11-16       Impact factor: 2.014

4.  Contribution of the Cytoplasmic Determinants of Vpu to the Expansion of Virus-Containing Compartments in HIV-1-Infected Macrophages.

Authors:  Olivier Leymarie; Leslie Lepont; Margaux Versapuech; Delphine Judith; Sophie Abelanet; Katy Janvier; Clarisse Berlioz-Torrent
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

5.  The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.

Authors:  Shilpi Sharma; Moein Jafari; Amandip Bangar; Karen William; John Guatelli; Mary K Lewinski
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

6.  Substitutions in Nef That Uncouple Tetherin and SERINC5 Antagonism Impair Simian Immunodeficiency Virus Replication in Primary Rhesus Macaque Lymphocytes.

Authors:  Sanath Kumar Janaka; Brian J Snow; Ryan T Behrens; David T Evans
Journal:  J Virol       Date:  2022-05-10       Impact factor: 6.549

7.  Tetherin Antagonism by HIV-1 Group M Nef Proteins.

Authors:  Juan F Arias; Marta Colomer-Lluch; Benjamin von Bredow; Justin M Greene; Julie MacDonald; David H O'Connor; Ruth Serra-Moreno; David T Evans
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

8.  Structural determination of virus protein U from HIV-1 by NMR in membrane environments.

Authors:  Hua Zhang; Eugene C Lin; Bibhuti B Das; Ye Tian; Stanley J Opella
Journal:  Biochim Biophys Acta       Date:  2015-09-08

9.  Pharmacologic Inhibition of Nedd8 Activation Enzyme Exposes CD4-Induced Epitopes within Env on Cells Expressing HIV-1.

Authors:  Andrey Tokarev; Charlotte Stoneham; Mary K Lewinski; Amey Mukim; Savitha Deshmukh; Thomas Vollbrecht; Celsa A Spina; John Guatelli
Journal:  J Virol       Date:  2015-12-16       Impact factor: 5.103

10.  Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness.

Authors:  Shilpa S Iyer; Frederic Bibollet-Ruche; Scott Sherrill-Mix; Gerald H Learn; Lindsey Plenderleith; Andrew G Smith; Hannah J Barbian; Ronnie M Russell; Marcos V P Gondim; Catherine Y Bahari; Christiana M Shaw; Yingying Li; Timothy Decker; Barton F Haynes; George M Shaw; Paul M Sharp; Persephone Borrow; Beatrice H Hahn
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.